Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: StemCells, Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies. The company operates two primary therapeutic programs: the CNS Program (developing HuCNS-SC cells for central nervous system disorders) and the Liver Program (developing human liver engrafting cells). Additionally, the company markets proprietary cell culture products under the SC Proven brand for academic and industrial research.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $993,000 | $232,000 |
| Net Loss | $(27,026,000) | $(29,087,000) |
| Loss Per Share (Basic & Diluted) | $(0.25) | $(0.35) |
| Research & Development Expenses | $19,930,000 | $17,808,000 |
| General & Administrative Expenses | $9,530,000 | $8,296,000 |
| Cash and Cash Equivalents (Year End) | $38,618,000 | $30,043,000 |
| Total Assets | $51,190,000 | $41,230,000 |
| Warrant Liability (Fair Value) | $9,677,000 | $8,440,000 |
| Accrued Wind-down Expenses | $4,433,000 | $5,513,000 |
Note: The company has not achieved profitability and expects to incur additional operating losses in the foreseeable future.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 328% to $993,000 in 2009 compared to $232,000 in 2008. This increase was primarily driven by the consolidation of revenues from the acquisition of Stem Cell Sciences Plc (SCS) operations in April 2009, which included product sales of approximately $385,000 (none in 2008).
- Net Loss Improvement: Net loss decreased to $27.0 million from $29.1 million in 2008. This improvement was largely due to a non-cash gain of $1.9 million related to the change in fair value of warrant liabilities, offsetting higher operating expenses.
- Operating Expenses: Total operating expenses increased 12% to $30.1 million. R&D expenses rose 12% due to the consolidation of SCS operations and increased personnel costs. SG&A expenses increased 15%, partly due to non-recurring acquisition costs of approximately $693,000.
- Acquisition: On April 1, 2009, the company acquired substantially all operating assets and liabilities of SCS for approximately $5.1 million (paid in stock and cash), expanding its enabling technologies portfolio and European presence.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The company does not provide specific financial guidance. Management expects to incur substantial operating losses in the future as it advances clinical trials and R&D. The company relies on external financing (equity/debt offerings) and grants to fund operations. As of December 31, 2009, cash reserves were approximately $38.6 million.
Clinical and Development Progress
- CNS Program: Completed a Phase I trial for Neuronal Ceroid Lipofuscinosis (NCL) showing safety and engraftment. Initiated a Phase I trial for Pelizaeus-Merzbacher Disease (PMD) in November 2009; first patient treated in February 2010.
- Liver Program: Deferred initiation of a clinical study for human liver engrafting cells (hLEC) pending process improvements.
- Enabling Technologies: Launched new cell culture media products (GS1-R and GS2-M) in early 2010.
Risks and Contingencies
- Liquidity Risk: The company has limited capital resources and must obtain significant additional capital to sustain operations. If funding is unavailable, the company may need to delay or eliminate R&D programs.
- Legal Proceedings: Ongoing patent infringement litigation against Neuralstem, Inc. regarding six patents. The company has offset litigation costs against future royalty payments to NeuroSpheres, Ltd.
- Wind-down Costs: Significant ongoing obligations related to a former facility in Rhode Island (lease through 2013). A reserve of $4.4 million was maintained at year-end.
- Warrant Liability: Warrants issued in 2008 and 2009 are classified as liabilities. Changes in their fair value significantly impact net income/loss (e.g., $1.9 million gain in 2009).
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $38.6 million cash balance against the projected burn rate of approximately $24.7 million in operating cash outflows for 2009.
- Rhode Island Facility: Confirm the status of subleasing efforts for the former Rhode Island facility, as the $4.4 million reserve is sensitive to vacancy rate assumptions.
- Neuralstem Litigation: Monitor the status of the patent infringement suits against Neuralstem, Inc., as the outcome could impact the company's IP portfolio and future revenue potential.
- Warrant Liability Volatility: Understand that net income is heavily influenced by non-cash mark-to-market adjustments on warrant liabilities, which fluctuate with stock price volatility.
- Revenue Sustainability: Assess the sustainability of the new product sales revenue ($385,000) derived from the SCS acquisition, as the company has no approved therapeutic products generating revenue.